With no person-to-person spread, the health risk to humans remaining low, and the 15-month emergency human response to H5N1 avian flu over, this summer’s ...

Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based ...

Company News Published 07/24/2025, 10:59 AM 0 Novavax’s H5N1 vaccine shows promise with single-dose option NVAX -4.67% ...

The Trump administration’s decision to terminate hundreds of millions of dollars to develop mRNA vaccines and treatments ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administrationPotential for single ...

Canadian doctors and scientists say Robert F. Kennedy Jr.'s defunding of mRNA vaccine development projects will have negative ...